Dan Zimbroff

1.8k total citations
21 papers, 1.3k citations indexed

About

Dan Zimbroff is a scholar working on Psychiatry and Mental health, Clinical Psychology and Experimental and Cognitive Psychology. According to data from OpenAlex, Dan Zimbroff has authored 21 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Psychiatry and Mental health, 12 papers in Clinical Psychology and 3 papers in Experimental and Cognitive Psychology. Recurrent topics in Dan Zimbroff's work include Schizophrenia research and treatment (16 papers), Healthcare Decision-Making and Restraints (12 papers) and Psychiatric care and mental health services (8 papers). Dan Zimbroff is often cited by papers focused on Schizophrenia research and treatment (16 papers), Healthcare Decision-Making and Restraints (12 papers) and Psychiatric care and mental health services (8 papers). Dan Zimbroff collaborates with scholars based in United States, Germany and United Kingdom. Dan Zimbroff's co-authors include John M. Kane, Robert D. McQuade, Mirza W. Ali, Г. Ингенито, William H. Carson, Anutosh Ranjan Saha, David G. Daniel, Carol A. Tamminga, B. Wallin and Kenneth B. Kashkin and has published in prestigious journals such as American Journal of Psychiatry, The Journal of Clinical Psychiatry and Journal of Clinical Psychopharmacology.

In The Last Decade

Dan Zimbroff

21 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dan Zimbroff United States 12 890 317 266 198 147 21 1.3k
Ronald Brenner United States 25 933 1.0× 175 0.6× 311 1.2× 282 1.4× 90 0.6× 60 1.6k
Robert A. Leadbetter United States 15 984 1.1× 294 0.9× 378 1.4× 116 0.6× 84 0.6× 22 1.5k
G.D. Tollefson United States 17 1.1k 1.3× 442 1.4× 455 1.7× 153 0.8× 183 1.2× 76 1.6k
WFSBP Task Force on Treatment Guide United States 8 1.1k 1.2× 274 0.9× 408 1.5× 98 0.5× 190 1.3× 8 1.4k
Philipp Rothe Germany 10 1.1k 1.2× 234 0.7× 242 0.9× 119 0.6× 119 0.8× 17 1.4k
Subramoniam Madhusoodanan United States 21 779 0.9× 175 0.6× 220 0.8× 95 0.5× 103 0.7× 62 1.5k
Pierre V. Trân United States 17 1.5k 1.7× 297 0.9× 616 2.3× 174 0.9× 175 1.2× 28 1.9k
Margaretta Nyilas United States 15 1.2k 1.3× 313 1.0× 427 1.6× 91 0.5× 108 0.7× 28 1.4k
Magdolna Tardy Germany 10 1.0k 1.1× 384 1.2× 205 0.8× 88 0.4× 132 0.9× 13 1.4k
Jack Hirschowitz United States 22 812 0.9× 144 0.5× 164 0.6× 272 1.4× 142 1.0× 63 1.4k

Countries citing papers authored by Dan Zimbroff

Since Specialization
Citations

This map shows the geographic impact of Dan Zimbroff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dan Zimbroff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dan Zimbroff more than expected).

Fields of papers citing papers by Dan Zimbroff

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dan Zimbroff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dan Zimbroff. The network helps show where Dan Zimbroff may publish in the future.

Co-authorship network of co-authors of Dan Zimbroff

This figure shows the co-authorship network connecting the top 25 collaborators of Dan Zimbroff. A scholar is included among the top collaborators of Dan Zimbroff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dan Zimbroff. Dan Zimbroff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zimbroff, Dan. (2008). Pharmacological Control of Acute Agitation. CNS Drugs. 22(3). 199–212. 21 indexed citations
2.
Currier, Glenn W., Leslie Citrome, Dan Zimbroff, et al.. (2007). Intramuscular Aripiprazole in the Control of Agitation. Journal of Psychiatric Practice. 13(3). 159–169. 20 indexed citations
3.
Daniel, David G., Glenn W. Currier, Dan Zimbroff, et al.. (2007). Efficacy and Safety of Oral Aripiprazole Compared with Haloperidol in Patients Transitioning from Acute Treatment with Intramuscular Formulations. Journal of Psychiatric Practice. 13(3). 170–177. 20 indexed citations
4.
Zimbroff, Dan, Ronald N. Marcus, George Manos, et al.. (2007). Management of Acute Agitation in Patients With Bipolar Disorder. Journal of Clinical Psychopharmacology. 27(2). 171–176. 70 indexed citations
5.
Zimbroff, Dan, Lewis Warrington, Antony Loebel, Ruoyong Yang, & Cynthia Siu. (2007). Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study. International Clinical Psychopharmacology. 22(6). 363–370. 40 indexed citations
6.
Feiger, Alan D., Karl Rickels, Moira A. Rynn, Dan Zimbroff, & Donald S. Robinson. (2006). Selegiline Transdermal System for the Treatment of Major Depressive Disorder. The Journal of Clinical Psychiatry. 67(9). 1354–1361. 67 indexed citations
7.
Zimbroff, Dan, Michael H. Allen, John Battaglia, et al.. (2005). Best Clinical Practice With Ziprasidone IM: Update After 2 Years of Experience. CNS Spectrums. 10(S11). 1–15. 27 indexed citations
8.
Currier, Glenn W., Michael H. Allen, E. Bradshaw Bunney, et al.. (2004). Standard therapies for acute agitation. Journal of Emergency Medicine. 27(4). S9–S12. 10 indexed citations
9.
Currier, Glenn W., Michael H. Allen, E. Bradshaw Bunney, et al.. (2004). Novel therapies for treating acute agitation. Journal of Emergency Medicine. 27(4). S13–S18. 3 indexed citations
10.
Currier, Glenn W., Michael H. Allen, E. Bradshaw Bunney, et al.. (2004). Future directions in research. Journal of Emergency Medicine. 27(4). S27–S29. 1 indexed citations
11.
Currier, Glenn W., Michael H. Allen, E. Bradshaw Bunney, et al.. (2004). Updated treatment algorithm. Journal of Emergency Medicine. 27(4). S25–S26. 5 indexed citations
12.
Currier, Glenn W., Michael H. Allen, E. Bradshaw Bunney, et al.. (2004). Safety of medications used to treat acute agitation. Journal of Emergency Medicine. 27(4). S19–S24. 3 indexed citations
13.
Currier, Glenn W., Michael H. Allen, E. Bradshaw Bunney, et al.. (2004). Intramuscular antipsychotics: Clinical experience review. Journal of Emergency Medicine. 27(4). S3–S4. 5 indexed citations
14.
Pande, Atul C., Jerri G. Crockatt, Douglas E. Feltner, et al.. (2003). Pregabalin in Generalized Anxiety Disorder: A Placebo-Controlled Trial. American Journal of Psychiatry. 160(3). 533–540. 244 indexed citations
15.
Zimbroff, Dan. (2003). Management of Acute Psychosis: From Emergency to Stabilization. CNS Spectrums. 8(S2). 10–15. 11 indexed citations
16.
Daniel, David G., Dan Zimbroff, R.H. Swift, & Edmund P. Harrigan. (2003). The tolerability of intramuscular ziprasidone and haloperidol treatment and the transition to oral therapy. International Clinical Psychopharmacology. 19(1). 9–15. 27 indexed citations
17.
Weiden, Peter J., Naveed Iqbal, Alan Mendelowitz, et al.. (2002). Best Clinical Practice with Ziprasidone: Update After One Year of Experience. Journal of Psychiatric Practice. 8(2). 81–97. 33 indexed citations
18.
Kane, John M., William H. Carson, Anutosh Ranjan Saha, et al.. (2002). Efficacy and Safety of Aripiprazole and Haloperidol Versus Placebo in Patients With Schizophrenia and Schizoaffective Disorder. The Journal of Clinical Psychiatry. 63(9). 763–771. 456 indexed citations
19.
Zimbroff, Dan, S. Brook, & I. Benattia. (2002). Safety and tolerability of IM ziprasidone: Review of clinical trial data. European Neuropsychopharmacology. 12. 294–294. 1 indexed citations
20.
Zimbroff, Dan, John M. Kane, Carol A. Tamminga, et al.. (1997). Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. American Journal of Psychiatry. 154(6). 782–791. 226 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ronald Brenner Breakdown of academic impact, for papers by Robert A. Leadbetter Breakdown of academic impact, for papers by G.D. Tollefson Breakdown of academic impact, for papers by WFSBP Task Force on Treatment Guide Breakdown of academic impact, for papers by Philipp Rothe Breakdown of academic impact, for papers by Subramoniam Madhusoodanan Breakdown of academic impact, for papers by Pierre V. Trân Breakdown of academic impact, for papers by Margaretta Nyilas Breakdown of academic impact, for papers by Magdolna Tardy Breakdown of academic impact, for papers by Jack Hirschowitz
Rankless by CCL
2026